assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than July 26, 2002.

A. Federal Reserve Bank of Richmond (A. Linwood Gill, III, Vice President) 701 East Byrd Street, Richmond, Virginia 23261–4528:

1. BB&T Corporation, Winston-Salem, North Carolina; to acquire 100 percent of the voting shares of Regional Financial Corporation, Tallahassee, Florida, and thereby indirectly acquire voting shares of First South Bank, Tallahassee, Florida, and thereby engage in operating a savings association, pursuant to § 225.28(b)(4)(ii) of Regulation Y.

Board of Governors of the Federal Reserve System, June 26, 2002.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc.02–16581 Filed 7–1–02; 8:45 am]

BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60-Day–02–66]

Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the CDC Reports Clearance Officer on (404) 498–1210.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. CDC is requesting an emergency clearance from the Office of Management and Budget (OMB) to collect data under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Send comments to Anne O'Connor, CDC Assistant Reports Clearance Officer, 1600 Clifton Road, MS D–24, Atlanta, GA 30333. Written comments should be received within 14 days of this notice. OMB is expected to act on the request of CDC within 21 days of publication of this notice.

Proposed Project

Notification of Possession of a Select Agent—New—Office of the Director, Office of Health and Safety (OD/OHS), Centers for Disease Control and Prevention (CDC). Section 202(a) of the Public Health Security and Bioterrorism Preparedness Response Act of 2002 (Public Law 107–188) requires that all persons in possession of a Select Agent notify the Secretary of Health and Human Services by September 10, 2002.

The Secretary of Health and Human Services has designated the CDC as the agency responsible for collecting this information. CDC is specifying that facilities, rather than persons, who possess a Select Agent shall notify CDC by completing the Application for Notice of Possession of a Select Agent. For the purposes of completing this application, a facility should be considered as a single geographic site, such as a building or complex of buildings at a single mailing address. Each facility should designate a responsible facility official (RFO) to complete this form. It is the responsibility of the RFO to ensure management oversight of this notification requirement. The RFO should be either a safety officer, a senior management official of the facility, or both, who has been authorized by the facility to complete and submit this application. The RFO should not be an individual who actually possesses, uses, or transfers such agents or toxins.

In order to complete the application, the RFO will need to inventory its facility and consult with others (*e.g.,* principal investigators) as necessary to obtain the information required for this application. The RFO must review and sign the application and will be the point of contact if CDC has questions concerning the application or other matters related to the Public Law. Facilities that do not possess a listed biological agent or toxin are required to complete the declaration of non-possession and submit the form.

Facilities that possess listed biological agents and/or toxins that are a threat to public health must submit their notification form to the Centers for Disease Control and Prevention (CDC), Office of Health and Safety, 1600 Clifton Road, MS A13, Atlanta, GA 30333. Facilities that possess listed biological agents that are deemed a threat to animal health or animal products are required to submit their form to the U.S. Department of Agriculture, Animal and Plant Health Inspection Service (APHIS), Veterinary Services, National Center for Import-Export, Products Program, 4700 Riverdale Road, Unit 40, Riverdale, MD 20737. Facilities that possess listed biological agents and/or toxins that are deemed a threat to both public health and animal health and animal products are required to submit their form to both CDC and APHIS. There is no cost to respondents except their time to complete the notification form.

Respondents	Number of Respondents	Number of responses/respondent	Avg. burden/response (in hours)	Total burden (in hours)
Facilities that do not possess listed biological agents and/or toxins	95,400	1	10/60	15,900

Respondents	Number of Respondents	Number of responses/respondent	Avg. burden/response (in hours)	Total burden (in hours)
Facilities that possess listed biological agents and/or toxins	94,600	1	2	189,200
Total				205,100

Dated: June 26, 2002.

Nancy E. Cheal,

Acting Associate Director for Policy, Planning and Evaluation, Centers for Disease Control and Prevention.

[FR Doc. 02–16674 Filed 7–1–02; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Science Advisory Board to the National Center for Toxicological Research; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Science Advisory Board (SAB) to the National Center for Toxicological Research (NCTR).

General Function of the Committee: The Board advises the Director, NCTR, on establishing, implementing, and evaluating the research programs that assist the Commissioner of Food and Drugs in fulfilling his regulatory responsibilities. The Board provides an extra agency review in ensuring that the research programs at NCTR are scientifically sound and pertinent.

Date and Time: The meeting will be held on August 8, 2002, from 1 p.m. to 5 p.m. and August 9, 2002, from 8 a.m. to 1 p.m.

Location: NCTR, Building #12, Conference Center, 3900 NCTR Dr., Jefferson, AR 72079.

Contact Person: Leonard M. Schechtman, NCTR (HFT–10), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–6696, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12559. Please call the Information Line for up-to-date information on this meeting.

Agenda: The Board will be presented with a draft report on the evaluation of the Division of Chemistry. The draft report is the product of a site visit team that conducted an onsite review of the Division in January. Division staffers will provide a preliminary response to the issues raised and recommendations made. The NCTR Director will provide a Center update and discuss the development of five newly established centers of excellence at the NCTR. These are the: Functional Genomics Center, Structural Genomics Center, Toxicoinformatics Center, Hepatotoxicity Center, and Phototoxicity Center. The Directors of each of these Centers will provide a presentation on the development and future of their respective center. A proposal presented to the Board at the June 2001 meeting regarding the establishment of a subcommittee on scientific opportunities to improve regulatory science through collaborations with external stakeholders will be revisited. The Board will receive an update on activities of an existing subcommittee with a similar focus (Advisory Committee for Pharmaceutical Science, Nonclinical Studies Subcommittee).

Procedure: On August 8, 2002, from 1 p.m. to 5 p.m., and August 9, 2002, from 8 a.m. to 12 noon, the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 31, 2002. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 noon, on August 9, 2002. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 31, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations. On August 9, 2002, from 12 noon to 1 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to permit discussion of information concerning individuals associated with the research programs at NCTR.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Leonard M. Schechtman at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: June 24, 2002.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 02–16588 Filed 7–1–02; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

National Vaccine Injury Compensation Program; List of Petitions Received

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Health Resources and Services Administration (HRSA) is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (''the Program''), as required by section 2112(b)(2) of the Public Health Service (PHS) Act, as amended. While the Secretary of Health and Human Services is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.

FOR FURTHER INFORMATION CONTACT: For information about requirements for filing petitions, and the Program in general, contact the Clerk, United States